[1] Ata-Ali J, Zurriaga O, Alberich C. Incidence and survival rates for malignant salivary gland tumors. J Oral Sci 2016;58:67–73.
[2] Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986;8:177–84.
[3] Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004;26:681–92; discussion 692–3.
[4] Lima RA, Tavares MR, Dias FL, et al. Clinical prognostic factors in malignant parotid gland tumors. Otolaryngol Head Neck Surg 2005;133:702–8.
[5] Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 2006;85:74
[6] Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005;63:917–28.
[7] Kaur J, Goyal S, Muzumder S, Bhasker S, Mohanti BK, Rath GK. Outcome of surgery and post-operative radiotherapy for major salivary gland carcinoma: ten year experience from a single institute. Asian Pac J Cancer Prev 2014;15:8259–63.
[8] Wahlberg P, Anderson H, Biorklund A, Moller T, Perfekt R. Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients. Oral Oncol 2002;38:706–13.
[9] Jang JY, Choi N, Ko YH, et al. Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1-2 N0 high-grade salivary gland cancer. BMC Cancer 2018;18:672.
[10] Ali S, Palmer FL, Katabi N, et al. Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. Laryngoscope 2017;127:2265–9.
[11] Qian K, Di L, Guo K, Zheng X, Ji Q, Wang Z. Cervical Lymph Node Metastatic Status and Adjuvant Therapy Predict the Prognosis of Salivary Duct Carcinoma. J Oral Maxillofac Surg 2018;76:1578–86.
[12] Yoo SH, Roh JL, Kim SO, et al. Patterns and treatment of neck metastases in patients with salivary gland cancers. J Surg Oncol 2015;111:1000–6.
[13] Johnston ML, Huang SH, Waldron JN, et al. Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. Head Neck 2016;38 Suppl 1:E820–6.
[14] Cerda T, Sun XS, Vignot S, et al. A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). Crit Rev Oncol Hematol 2014;91:142–58.
[15] Storey MR, Garden AS, Morrison WH, Eicher SA, Schechter NR, Ang KK. Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 2001;51:952–8.
[16] North CA, Lee DJ, Piantadosi S, Zahurak M, Johns ME. Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1990;18:1319–26.
[17] Pohar S, Gay H, Rosenbaum P, et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. Int J Radiat Oncol Biol Phys 2005;61:112–8.
[18] Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005;61:103–11.
[19] Toonkel LM, Guha S, Foster P, Dembrow V. Radiotherapy for parotid cancer. Ann Surg Oncol 1994;1:468–72.
[20] Fitzpatrick PJ, Theriault C. Malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 1986;12:1743–7.
[21] Bhide SA, Miah A, Barbachano Y, Harrington KJ, Newbold K, Nutting CM. Radical radiotherapy for treatment of malignant parotid tumours: a single centre experience. 1995–2005. Br J Oral Maxillofac Surg 2009;47:284–9.
[22] Chen JL, Huang YS, Kuo SH, et al. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma. Oncotarget 2017;8:14068–77.
[23] Hosni A, Huang SH, Goldstein D, et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol 2016;54:75–80.
[24] van der Veen J, Nuyts S. Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma? Cancers. 2017;9(10). pii: E135.
[25] Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12:127–36.
[26] Samant S, van den Brekel MW, Kies MS, et al. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head Neck 2012;34:1263–8.
[27] Hosal AS, Fan C, Barnes L, Myers EN. Salivary duct carcinoma. Otolaryngol Head Neck Surg 2003;129:720–5.
[28] Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA. Stage as major long term outcome predictor in minor salivary gland carcinoma. Cancer 2000;89:1195–204.
[29] Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 2009;135:687–92.
[30] Maruya S, Namba A, Matsubara A, et al. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol 2006;11:403–6.
[31] Hsieh CE, Lin CY, Lee LY, et al. Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat Oncol 2016;11:47.
[32] Schoenfeld JD, Sher DJ, Norris CM, et al. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2012;82:308–14.
[33] Tanvetyanon T, Fisher K, Caudell J, Otto K, Padhya T, Trotti A. Adjuvant chemoradiotherapy versus with radiotherapy alone for locally advanced salivary gland carcinoma among older patients. Head Neck 2016;38:863–70.